Atrium Therapeutics initiated with an Overweight at Wells Fargo

Wells Fargo analyst Yanan Zhu initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target The firm sees a “significant” opportunity for the company’s’ antibody oligonucleotide conjugates platform in genetic cardiomyopathy. Atrium’s lead programs for PRKAG2 syndrome and phospholamban cardiomyopathy are addressing high unmet needs and have shown “compelling” preclinical data, the analyst tells investors in a research note.